Wing Keung Chan
Immunology and Microbiology · The Ohio State University
Publications
131
Citations
2,651
Est. group size
~30
Recurring co-author estimate
Active years
33
Publishing since 1994
Wing Keung Chan's research focuses on immune cells that fight cancer, particularly natural killer (NK) cells and innate lymphoid cells (ILCs), and how they can be engineered or activated for therapies against blood cancers like leukemia and lymphoma, as well as solid tumors such as neuroblastoma. Work also covers genetic engineering methods (including CAR designs and iPSC-based approaches) used to build improved cell therapies. This research sits at the intersection of immunology, cancer biology, and cell engineering.
Publication output was low and sporadic from 2017-2022 but increased sharply starting in 2023, with sustained high output through 2025, suggesting a recent period of growing research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Editorial: Novel chimeric antigen receptor (CAR) designs in engineering NK cells for cancer
Frontiers in Immunology · 2026
- Genetic engineering strategies for cell-based therapy: viral, non-viral, and precision genome editing technologies
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY · 2026
- Prdm1 positively regulates liver Group 1 ILCs cancer immune surveillance and preserves functional heterogeneity
eLife · 2024
- Sepsis induced dysfunction of liver type 1 innate lymphoid cells
BMC Immunology · 2024
- Prdm1 Positively Regulates Liver Type 1 ILCs Cancer Immune Surveillance and Preserves Functional Heterogeneity
eLife · 2024
- Reviewer #1 (Public Review): Prdm1 Positively Regulates Liver Group 1 ILCs Cancer Immune Surveillance and Preserves Functional Heterogeneity
2024
- Author response: Prdm1 Positively Regulates Liver Group 1 ILCs Cancer Immune Surveillance and Preserves Functional Heterogeneity
2024
- Prdm1 Positively Regulates Liver Group 1 ILCs Cancer Immune Surveillance and Preserves Functional Heterogeneity
eLife · 2024
- Reviewer #2 (Public Review): Prdm1 Positively Regulates Liver Group 1 ILCs Cancer Immune Surveillance and Preserves Functional Heterogeneity
2024
- Author response: Prdm1 positively regulates liver Group 1 ILCs cancer immune surveillance and preserves functional heterogeneity
2024
- Prdm1 positively regulates liver Group 1 ILCs cancer immune surveillance and preserves functional heterogeneity
eLife · 2024
- iPSC-mediated genetic manipulation promotes natural killer cell-centered cancer immunotherapy
Microbes & Immunity · 2024
- Supplementary Table 1 from <i>Ex Vivo</i> Activation of CD56<sup>+</sup> Immune Cells That Eradicate Neuroblastoma
2023
- Supplementary Figure 1 from <i>Ex Vivo</i> Activation of CD56<sup>+</sup> Immune Cells That Eradicate Neuroblastoma
2023
- Supplementary Figure Legend from <i>Ex Vivo</i> Activation of CD56<sup>+</sup> Immune Cells That Eradicate Neuroblastoma
2023
- Blood×8
- The Journal of Immunology×4
- Blood Advances×4
- eLife×4
- Experimental Hematology and Oncology×2
- Jianhua Yu
Immunology and Microbiology · The Ohio State University
- Dean A. Lee
Immunology and Microbiology · The Ohio State University
- Jilu Zhang
Immunology and Microbiology · Indiana University
- Kyle B. Lupo
Immunology and Microbiology · Purdue University West Lafayette
- Meisam Naeimi Kararoudi
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile